Literature DB >> 17366219

Determining risk in pediatric research with no prospect of direct benefit: time for a national consensus on the interpretation of federal regulations.

Celia B Fisher1, Susan Z Kornetsky, Ernest D Prentice.   

Abstract

United States federal regulations for pediatric research with no prospect of direct benefit restrict institutional review board (IRB) approval to procedures presenting: 1) no more than "minimal risk" ( section sign 45CFR46.404); or 2) no more than a "minor increase over minimal risk" if the research is commensurate with the subjects' previous or expected experiences and intended to gain vitally important information about the child's disorder or condition ( section sign 45CFR46.406) (DHHS 2001). During the 25 years since their adoption, these regulations have helped IRBs balance subject protections with the pursuit of scientific knowledge to advance children's welfare. At the same time, inconsistency in IRB application of these regulations to pediatric protocols has been widespread, in part because of the ambiguity of the regulatory language. During the past decade, three federally-charged committees have addressed these ambiguities: 1) the National Human Research Protections Advisory Committee (NHRPAC) (Washington, DC), 2) the Institute of Medicine (IOM) Committee on the Ethical Conduct of Clinical Research Involving Children (Washington, DC); and 3) the United States Department of Health and Human Services Secretary's Advisory Committee for Human Research Protections (SACHRP) (Washington, DC). The committees have reached similar conclusions on interpretation of language within regulations section sign section sign 45CFR46.404 and 406; these conclusions are remarkably consistent with recent international recommendations and those of the original National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1977) report from which current regulations are based. Drawing on the committees' public reports, this article identifies the ethical issues posed by ambiguities in regulatory language, summarizes the committees' deliberations, and calls for a national consensus on recommended criteria.

Entities:  

Mesh:

Year:  2007        PMID: 17366219     DOI: 10.1080/15265160601171572

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  14 in total

1.  Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.

Authors:  Inmaculada de Melo-Martín; Dolan Sondhi; Ronald G Crystal
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

2.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

3.  Minimal Risk in Pediatric Research: A Philosophical Review and Reconsideration.

Authors:  John Rossi; Robert M Nelson
Journal:  Account Res       Date:  2017-08-04       Impact factor: 2.622

4.  Do U.S. regulations allow more than minor increase over minimal risk pediatric research? Should they?

Authors:  David Wendler
Journal:  IRB       Date:  2013 Nov-Dec

5.  Reducing Health Disparities and Enhancing the Responsible Conduct of Research Involving LGBT Youth.

Authors:  Celia B Fisher; Brian Mustanski
Journal:  Hastings Cent Rep       Date:  2014-09       Impact factor: 2.683

6.  Ethics of clinical research with mentally ill persons.

Authors:  Hanfried Helmchen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-01-03       Impact factor: 5.270

7.  When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials.

Authors:  Inmaculada de Melo-Martín; Dolan Sondhi; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2011-05-19       Impact factor: 5.695

8.  Measuring Discomfort in Health Research Relative to Everyday Events and Routine Care: An Application to Sexual and Gender Minority Youth.

Authors:  Kathryn Macapagal; Emily Bettin; Margaret Matson; Ashley Kraus; Celia B Fisher; Brian Mustanski
Journal:  J Adolesc Health       Date:  2019-01-04       Impact factor: 5.012

9.  Minimal risk in research involving pregnant women and fetuses.

Authors:  Carson Strong
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

10.  "I Won't Out Myself Just to Do a Survey": Sexual and Gender Minority Adolescents' Perspectives on the Risks and Benefits of Sex Research.

Authors:  Kathryn Macapagal; Ryan Coventry; Miriam R Arbeit; Celia B Fisher; Brian Mustanski
Journal:  Arch Sex Behav       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.